Enzyme-responsive hybrid prodrug of nitric oxide and hydrogen sulfide for heart failure therapy-Reference-Cited by-同舟云学术

Enzyme-responsive hybrid prodrug of nitric oxide and hydrogen sulfide for heart failure therapy

Published:2022 Issue:53 Volume:58 Page:7396-7399
ISSN:1359-7345
Container-title:Chemical Communications
language:en
Short-container-title:Chem. Commun.

Author:

Liu Qi¹,Ji Guangbo¹,Chu Yushu¹,Hao Tian¹,Qian Meng¹,Zhao Qiang¹^ORCID

Affiliation:

1. State key Laboratory of Medicinal Chemical Biology, Haihe Laboratory of Sustainable Chemical Transformations, Key Laboratory of Bioactive Materials (Ministry of Education), Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin 300071, China

Abstract

Codelivery of nitric oxide and hydrogen sulfide from an enzyme-responsive hybrid prodrug provides potent therapeutic efficacy for heart failure.

Funder

Natural Science Foundation of Tianjin City

National Natural Science Foundation of China

National Key Research and Development Program of China

Publisher

Royal Society of Chemistry (RSC)

Subject

Materials Chemistry,Metals and Alloys,Surfaces, Coatings and Films,General Chemistry,Ceramics and Composites,Electronic, Optical and Magnetic Materials,Catalysis

Link

http://pubs.rsc.org/en/content/articlepdf/2022/CC/D2CC02267B

Reference34 articles.

1. Heart Failure With Reduced Ejection Fraction

2. The Medical and Device-Related Treatment of Heart Failure

3. Heart failure drug treatment: the fantastic four

4. Nitric oxide signalling in cardiovascular health and disease

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Codelivery of Gaseous Signaling Molecules for Biomedical Applications;ChemPlusChem;2024-04-13

2. Transformable binary-prodrug nanoparticles harness heterogeneity of neutrophils to overcome multidrug resistance and promote pyroptosis in cancer;Applied Materials Today;2024-04

3. Recent advances on the development of NO-releasing molecules (NORMs) for biomedical applications;European Journal of Medicinal Chemistry;2024-03

4. Doxorubicin prodrug-based nanomedicines for the treatment of cancer;European Journal of Medicinal Chemistry;2023-10

5. Hydrogen sulfide: Recent development of its dual donors and hybrid drugs;British Journal of Pharmacology;2023-09